IDEAYA Biosciences has reached a major milestone as the U.S. FDA grants Breakthrough Therapy designation (BTD) for darovasertib, a novel PKC inhibitor designed to treat primary uveal melanoma (UM) in patients facing enucleation. This recognition highlights darovasertib’s potential to offer a groundbreaking neoadjuvant therapy, addressing a critical gap for those with no FDA-approved systemic treatments. Encouraged by Phase 2 clinical data, which showed an 82% tumor shrinkage rate and a 61% eye preservation rate, IDEAYA is preparing for a Phase 3 registrational trial in 2025.
Dr. Darrin Beaupre, Chief Medical Officer of IDEAYA, emphasized the urgency of delivering new options to patients with limited treatment choices, while CEO Yujiro S. Hata confirmed the company’s commitment to presenting further clinical insights at key medical conferences this year. With additional studies on darovasertib’s combination therapy with crizotinib already in progress, this latest FDA designation paves the way for a faster regulatory path, potentially bringing a transformative solution to thousands of patients across North America, Europe, and Australia.
